CClinicalTrials.gg
CompletedNCT06255821Updated Jan 30, 2026

The Effect of Time on Generalization of Exposure-based Benefit

An interventional study of Exposure in One Week Follow-up Assessment, Six Weeks Follow-up Assessment and Three Months Follow-up Assessment, sponsored by Ruhr University of Bochum. Completed at 1 site in Germany. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-01-30.

Sponsored by Ruhr University of Bochum · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
59
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

Participants will receive a pre-assessment and an exposure with a control spider. This control spider will be presented again at post-training assessments. Participants will then be assigned to one of the follow-up assessments: one week, six weeks or three months. The control spider (spider A) and a novel spider (spider B) will be used again at follow-up BATs to test for generalization of exposure effects.

Read the detailed description

Several findings from basic research on extinction learning undermine the role of time effects in the contextualization and retrieval of extinguished memories (Archbold et al., 2013; Quirk, 2002; Wiltgen \& Silva, 2007). The latter bears important implications for the evaluation of short- and long-term effects of exposure-based fear reduction and generalization. To date, no study exists examining the role of time on the fear responding to treated stimuli and/or untreated stimuli after successful exposure. It will be investigated whether the differential responding to treated and untreated stimuli after exposure is dependent on the passage of time.

Spider fearful participants will be subjected to a standardized one-session treatment with spiders serving as treatment stimuli. Fear reduction towards treatment stimuli will be assessed at post-treatment. Furthermore, generalization of exposure therapy towards untreated stimuli (i.e., a novel spider) will be assessed. The extent of generalization of exposure-based fear reduction to untreated stimuli will be compared between three groups that will differ with respect to the follow-up length. Here, participants undergoing exposure will be randomly assigned to one of the following follow-up measurements: one week follow-up, six weeks follow-up, and three months follow-up. The extent of exposure induced fear reduction and generalization will be assessed and compared between these groups.

02

Conditions studied

  • One Week Follow-up Assessment
  • Six Weeks Follow-up Assessment
  • Three Months Follow-up Assessment

Browse trials for

Keywords

  • Exposure Therapy
  • Generalization of Exposure Effects
  • Fear of Spiders
  • Anxiety Disorders
  • Extinction
  • Specific phobia
03

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Presence of fear of spiders (Potential diagnosis of arachnophobia)

Exclusion criteria

Exclusion Criteria:

  • Reaching level 10 or higher in the initial (Pre-Exposure) Spider BAT
  • Any acute or chronic mental and / or somatic disease
  • Psychological, psychiatric, neurological or pharmacological treatment
  • Drug or alcohol abuse
  • Pregnancy
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    One week follow-up assessment

    Participants will receive a pre-assessment and an exposure with a control spider (spider A). This control spider will be presented again at post-training assessments. Participants will then be assigned to the follow-up assessment one week after the exposure session, in which spider A and a novel spider (spider B) will be used to test for generalization of exposure effects.

    Behavioral: Exposure

  • Experimental
    Six weeks follow-up assessment

    Participants will receive a pre-assessment and an exposure with a control spider (spider A). This control spider will be presented again at post-training assessments. Participants will then be assigned to the follow-up assessment six weeks after the exposure session, in which spider A and a novel spider (spider B) will be used to test for generalization of exposure effects.

    Behavioral: Exposure

  • Experimental
    Three months follow-up assessment

    Participants will receive a pre-assessment and an exposure with a control spider (spider A). This control spider will be presented again at post-training assessments. Participants will then be assigned to the follow-up assessment three months after the exposure session, in which spider A and a novel spider (spider B) will be used to test for generalization of exposure effects.

    Behavioral: Exposure

Interventions

  • BehavioralExposure

    One-session of graded in-vivo exposure with a spider. Each task is first modeled by the experimenter. Prior to the exposure, participants receive psychoeducation on anxiety and phobias.

05

What researchers measure

Primary outcomes

  1. Behavioral Approach Test (BAT)

    Change in the Behavioral Approach Test (BAT) at post-assessment and follow-up with the control spider (spider A; treated stimulus) and a novel spider (spider B; untreated fear stimulus). During the Behavioral Approach Test (BAT) the closest distance to a spider is measured.

    Time frame: Pre-assessment (immediately before exposure), post-assessment (one day after exposure), follow-up (one week, six weeks, or three months after exposure)

  2. Subjective fear

    Change in subjective fear at post-assessment and follow-up with the control spider (spider A; treated stimulus) and a novel spider (spider B; untreated fear stimulus) is measured during the Behavioral Approach Tests.

    Time frame: Pre-assessment (immediately before exposure), post-assessment (one day after exposure), follow-up (one week, six weeks, or three months after exposure)

  3. Subjective disgust

    Change in subjective disgust at post-assessment and follow-up with the control spider (spider A; treated stimulus) and a novel spider (spider B; untreated fear stimulus) is measured during the Behavioral Approach Tests.

    Time frame: Pre-assessment (immediately before exposure), post-assessment (one day after exposure), follow-up (one week, six weeks, or three months after exposure)

  4. Heart rate

    Change in heart rate at post-assessment and follow-up with the control spider (spider A; treated stimulus) and a novel spider (spider B; untreated fear stimulus) is measured during the Behavioral Approach Tests.

    Time frame: Pre-assessment (immediately before exposure), post-assessment (one day after exposure), follow-up (one week, six weeks, or three months after exposure)

Secondary outcomes

  1. Score on General Self-efficacy (GSE) Scale

    Change in self-efficacy is measured by the GSE Scale. The GSE Scale contains ten items and measures how confident the person feels to overcome difficult situations based on their self-assessed competence. The total score is determined by summing up all item scores, which results in a score between 10 and 40, where the higher scores represent higher GSE.

    Time frame: Pre-assessment (immediately before exposure), post-assessment (one day after exposure), follow-up (one week, six weeks, or three months after exposure)

  2. Self-efficacy Questionnaire for Phobic Situations (SEQ-SP)

    The questionnaire consists of 13 items. The items describe specific phobic situations (in relation to animals) for which the participants has to assess their self-efficacy expectations based on a five-point scale (1 = really sure I couldn't, 5 = really sure I could).

    Time frame: Pre-assessment (immediately before exposure), post-assessment (one day after exposure), follow-up (one week, six weeks, or three months after exposure)

  3. Fear of Spiders Questionnaire (FSQ)

    Change in the Spider-fear related questionnaires. The Fear of Spiders Questionnaire (FSQ) will be applied. Scores on this scale range from 0 to 108, with higher scores indicating greater fear of spiders.

    Time frame: Pre-assessment (immediately before exposure), post-assessment (one day after exposure), follow-up (one week, six weeks, or three months after exposure)

  4. Spider Fear Questionnaire (SPQ)

    The Spider Fear Questionnaire (SPQ) will be applied. Scores on this scale range from 0 to 31, with higher scores indicating greater fear of spiders.

    Time frame: Pre-assessment (immediately before exposure), post-assessment (one day after exposure), follow-up (one week, six weeks, or three months after exposure)

  5. Spider Beliefs Questionnaire (SBQ)

    The Spider Beliefs Questionnaire (SBQ) will be applied. Scores on this scale range from 0 to 100, with higher scores indicating greater fear of spiders.

    Time frame: Pre-assessment (immediately before exposure), post-assessment (one day after exposure), follow-up (one week, six weeks, or three months after exposure)

06

Study locations

1 site
  • Department of Behavioral and Clinical Neuroscience
    Bochum, 44787, Germany
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT06255821
Lead sponsor
Ruhr University of Bochum
Responsible party
Iris Kodzaga (Principal Investigator, Ruhr University of Bochum) — Principal investigator
First posted
Feb 13, 2024
Start date
Jul 8, 2024
Primary completion
Feb 19, 2025
Completion
Feb 19, 2025
Last update
Jan 30, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion